Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents

被引:0
|
作者
Gonzalez-Lama, Yago [1 ]
Isabel Vera, Maria [1 ]
Calvo, Marta [1 ]
Abreu, Lluis [1 ]
机构
[1] Hosp Univ Puerta Hierro, Serv Gastroenterol & Hepatol, Unidad Enfermedad Inflamatoria Intestinal, Madrid, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2010年 / 33卷 / 06期
关键词
Crohn's disease; Ulcerative colitis; Azathioprine; Infliximab; Adalimumab; FISTULIZING CROHNS-DISEASE; REFRACTORY ULCERATIVE-COLITIS; SCHEDULED MAINTENANCE TREATMENT; SINGLE-CENTER EXPERIENCE; LONG-TERM EFFICACY; INFLIXIMAB THERAPY; MAGNETIC-RESONANCE; FECAL CALPROTECTIN; PREDICTIVE FACTORS; RANDOMIZED-TRIAL;
D O I
10.1016/j.gastrohep.2009.11.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Immunosuppressive or biological treatment in patients with inflammatory bowel disease can modify the natural history of their disease, although these treatments are not universally effective and can have severe adverse effects. Attempts have been made to identify predictive factors of response to the various therapeutic options in order to aid the choice of the most appropriate therapeutic alternative in each patient. The possibility of modifying any one of these predictive factors would be of great interest since it would provide the opportunity to alter the course of the disease. Epidemiological, biological, clinical, endoscopic, radiological, genetic and even proteomic markers have been studied, in addition to others related to the disease itself or to specific treatments. The present article briefly discusses the real use of each of these markers and the evidence supporting their utility. (C) 2009 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 50 条
  • [31] Weight and body mass index patterns in a cohort of patients with inflammatory bowel disease treated with biological agents
    Kaazan, P.
    Tan, Z.
    Maiyani, P.
    Mickenbecker, M.
    Edwards, S.
    Mcivor, C.
    Andrews, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 105 - 106
  • [32] Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents
    Conley, Thomas E.
    Probert, Chris
    Subramanian, Sreedhar
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (12): : 1794 - 1795
  • [33] Review article: monitoring of immunomodulators in inflammatory bowel disease
    Aberra, FN
    Lichtenstein, GR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 307 - 319
  • [34] H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
    Rahier, Jean-Francois
    Papay, Pavol
    Salleron, Julia
    Sebastian, Shaji
    Marzo, Manuela
    Peyrin-Biroulet, Laurent
    Garcia-Sanchez, Valle
    Fries, Walter
    van Asseldonk, Dirk P.
    Farkas, Klaudia
    de Boer, Nanne K.
    Sipponen, Taina
    Ellul, Pierre
    Louis, Edouard
    Peake, Simon T. C.
    Kopylov, Uri
    Maul, Jochen
    Makhoul, Badira
    Fiorino, Gionata
    Yazdanpanah, Yazdan
    Chaparro, Maria
    GUT, 2011, 60 (04) : 456 - 462
  • [35] NEW OR RECURRENT CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH IMMUNOMODULATORS OR BIOLOGICS AFTER CANCER
    Mancone, R.
    Neri, B.
    Fiorillo, M.
    Moscardelli, A.
    Galbusera, A.
    Schiavone, S. C.
    Festa, S.
    Migliozzi, S.
    Marafini, I
    Lolli, E.
    Calabrese, E.
    Monteleone, G.
    Biancone, L.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S243 - S244
  • [36] Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
    Papa, Alfredo
    Scaldaferri, Franco
    Covino, Marcello
    Tursi, Antonio
    Furfaro, Federica
    Mocci, Giammarco
    Lopetuso, Loris Riccardo
    Maconi, Giovanni
    Bibbo, Stefano
    Fiorani, Marcello
    Laterza, Lucrezia
    Mignini, Irene
    Napolitano, Daniele
    Parisio, Laura
    Pizzoferrato, Marco
    Privitera, Giuseppe
    Pugliese, Daniela
    Schepis, Tommaso
    Schiavoni, Elisa
    Settanni, Carlo Romano
    Vetrone, Lorenzo Maria
    Armuzzi, Alessandro
    Danese, Silvio
    Gasbarrini, Antonio
    BIOMEDICINES, 2022, 10 (04)
  • [37] Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents
    Krusinski, Adam
    Grzywa-Celinska, Anna
    Szewczyk, Katarzyna
    Grzycka-Kowalczyk, Luiza
    Emeryk-Maksymiuk, Justyna
    Milanowski, Janusz
    INTERNATIONAL JOURNAL OF INFLAMMATION, 2021, 2021
  • [38] The Role of Serological Markers in the Prediction of Disease Course and Response to Therapy in Inflammatory Bowel Disease
    Reghefaoui, Maiss
    Peresuodei, Tariladei S.
    Palacios, Michell S. Saavedra
    Gill, Abhishek
    Orji, Chijioke
    Reghefaoui, Tiba
    Mostafa, Jihan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [39] Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
    Lauro, Rita
    Mannino, Federica
    Irrera, Natasha
    Squadrito, Francesco
    Altavilla, Domenica
    Squadrito, Giovanni
    Pallio, Giovanni
    Bitto, Alessandra
    BIOMEDICINES, 2021, 9 (12)
  • [40] Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review
    Ballesta-Lopez, Octavio
    Gil-Candel, Mayte
    Centelles-Oria, Maria
    Megias-Vericat, Juan Eduardo
    Solana-Altabella, Antonio
    Ribes-Artero, Hugo
    Nos-Mateu, Pilar
    Garcia-Pellicer, Javier
    Poveda-Andres, Jose Luis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)